COVID-19 Update:Learn more about how we are protecting our patients, families and staff, as well as other important facts about COVID-19.
Pediatric Malignant Peripheral Nerve Sheath Tumors
Malignant peripheral nerve sheath tumors (tumors that develop in the cells surrounding the nerves on the brain and spinal cord) may occur in up to 5% of patients with neurofibromatosis during their lifetime. These tumors are thought to arise predominantly from congenital plexiform neurofibromas and usually do not develop until late in the teenage years or early in adulthood. In an area of a known plexiform neurofibroma (skin tumor), there should be concern of malignant transformation into a malignant peripheral nerve sheath tumor if there is sudden enlargement of the lesion or if there is new onset pain or neurologic or physical compromise.
Diagnosis of Malignant Peripheral Nerve Sheath Tumors
Diagnosing a malignant transformation of a peripheral nerve sheath tumor can be difficult. A tumor may become malignant if an MRI scan shows significant enlargement or new enhancement (dye being taken up) of a portion of the tumor. A PET scan (positron emission tomography) can be useful if a portion of the growth is found to be 'hot' (metabolically active) on the PET scan. Often, at least a biopsy (removing cells or tissue to examine them),if not an excision (completely removing a tissue, organ or tumor from the body) is required to confirm the diagnosis of a malignant peripheral nerve sheath tumor. In cases where diagnosis is unclear, at least a biopsy should be performed to rule out malignant transformation.
Treatment for Malignant Peripheral Nerve Sheath Tumors
The treatment for malignant peripheral nerve sheath tumors continues to evolve. Patients have the best outcomes if tumors can be fully removed. This does not, however, ensure long-term disease control. Other therapies used to try to control malignant peripheral nerve sheath tumors, especially those, which are only partially resected, include multi-agent chemotherapy and radiation therapy (in selected cases). Children's National Hospital in cooperation with the Children's Oncology Group and the National Cancer Institute, are performing a series of innovative studies in attempts to create better therapies. Children's National is collaborating with the Department of Defense Neurofibromatosis Clinical Trials Consortium.
Senior Vice President, Center for Neuroscience and Behavioral Medicine
Director, Gilbert Neurofibromatosis Institute
Director, Brain Tumor Institute
We bring together a comprehensive team of pediatric oncology and neurology experts, giving children with brain tumors effective, personalized care.
Learn more about our world-renowned Gilbert Family Neurofibromatosis Institute, which helps children with neurofibromatosis type 1 or 2 live more normal lives.
Share your birthday with a child. Celebrate your life, and give a chance to someone who desperately wants to have as many as you.
Make it happen
Zhen Chao, now called Maddox, was born in China with a genetic condition called neurofibromatosis type 1 (NF1) that can cause painful or disfiguring tumors called plexiform neurofibromas. Read about Maddox.
Read More of Maddox's Story